A phase I study of ICT03-Es5 for the treatment of solid tumors.

Trial Profile

A phase I study of ICT03-Es5 for the treatment of solid tumors.

Planning
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs ICT03 Es5 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 28 Jul 2016 New trial record
    • 23 Jul 2016 According to a Incanthera media release, the company plans to initiate the trial in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top